ABIVAX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.82 EUR | +0.54% |
|
+4.66% | +50.92% |
| Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
| Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
Business Summary
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Number of employees: 61
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 23-05-04 | |
Didier Blondel
DFI | Director of Finance/CFO | - | 17-01-01 |
Sheldon Sloan
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-28 |
Didier Scherrer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Patrick Malloy
IRC | Investor Relations Contact | - | 23-08-22 |
Ida Hatoum
HRO | Human Resources Officer | - | 23-06-05 |
Michael Ferguson
PRN | Corporate Officer/Principal | - | 23-04-17 |
| Corporate Officer/Principal | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 13-12-03 | |
Kinam Hong
BRD | Director/Board Member | - | - |
Troy Ignelzi
BRD | Director/Board Member | 56 | 23-07-10 |
| Chief Executive Officer | 66 | 23-05-04 | |
Carol Brosgart
BRD | Director/Board Member | 72 | 18-01-21 |
June Lee
BRD | Director/Board Member | 58 | 23-07-10 |
| Director/Board Member | - | 16-12-31 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 62,928,818 | 56,795,436 ( 90.25 %) | 11,339 ( 0.0180 %) | 90.25 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
ABIVAX 0.02% | 12,951 | 0.02% | 187,427 $ |
Company contact information
Sector
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.82
EUR
Average target price
35.74
EUR
Spread / Average Target
+141.16%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +50.92% | 995M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ABVX Stock
- Company Abivax
